BLI801 (Braintree Laboratories, 1c0815)

BLI801 is an investigational oral laxative developed by Braintree Laboratories (now part of Sebela Pharmaceuticals) for the treatment of non-idiopathic constipation. Non-idiopathic constipation refers to bowel dysfunction that is a secondary side effect of other medications rather than a primary gastrointestinal disorder. As a product of Braintree Laboratories, which specializes in gastroenterology and bowel preparations, BLI801 is designed as an osmotic agent that increases the water content and volume of stool to facilitate bowel movements. The drug was evaluated in a pilot clinical study (NCT02442180) to assess its safety and efficacy in adults experiencing constipation induced by their medical regimens. Although the input name provided includes 'Humulin R U-100' (a brand of insulin regular), that component is unrelated to the development or therapeutic indication of BLI801.

Other names

BLI801 LaxativeBLI-801 LaxativeBLI 801 Laxative